scholarly journals Methylphenidate: A Review

2021 ◽  
pp. 05-14
Author(s):  
Vinicius Faustino Lima de Oliveira ◽  
Danilo José Silva Moreira ◽  
Juliana Brito da Fonseca ◽  
Karoline Rossi ◽  
Suzana dos Santos Vasconcelos ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Attention Deficit Hyperactivity Disorder ◽  
Nervous System ◽  
Adverse Effects ◽  
Adverse Events ◽  
Racemic Mixture ◽  
Institutional Repositories ◽  
Hyperactivity Disorder ◽  
The Central Nervous System ◽  
Pharmacologically Active

Methylphenidate (MFD) is an amphetamine-derived medicine that stimulates the Central Nervous System (CNS), promoting increased attention, less distraction and increased sense of motivation. This study aims to describe the main pharmaceutical characteristics of MFD, highlight the clinical indications for the use of MFD and detail the possible adverse events arising from the consumption of MFD. For this, we conducted a research in the databases ScienceResearch.com, SciELO, LILACS, PubMed and EMBASE and in the institutional repositories of the Federal University of São Paulo, Federal University of Minas Gerais and Federal University of Ceará, using the keywords and associations “methylphenidate”, “ritalin”, “effects” and “effects”. It was evidenced that the drug consists of a racemic mixture formed by four stereoisomers, and the pharmacologically active compound is racemate dextrogyl (d,l)-treo-MFD. It acts on the blockade of dopamine and norepinephrine transporters from the CNS, promoting effects that justify its prescription to treat Attention Deficit Hyperactivity Disorder (ADHD). In recent years, its consumption for non-therapeutic purposes has increased. Some adverse effects of its use have been reported, and insomnia, irritability and headache have been reported.

scholarly journals Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter

2021 ◽  
Vol 2021 (9) ◽  
Author(s):  
Hiroshi Kataoka ◽  
Daisuke Shimada ◽  
Hitoki Nanaura ◽  
Kazuma Sugie
Keyword(s):  
Central Nervous System ◽  
Cell Death ◽  
Nervous System ◽  
Monoclonal Antibodies ◽  
Programmed Cell Death ◽  
Adverse Effects ◽  
Neuromuscular Disorders ◽  
Neurological Complications ◽  
Programmed Cell Death 1 ◽  
The Central Nervous System

ABSTRACT This case is the first document to describe a patient receiving anti-programmed cell death 1 (PD-1) antibodies which showed cranial dura matter involvement. According to the increasing use of anti-PD-1 monoclonal antibodies, adverse effects can occur in several organs since its ligand PD-L1 and PD-L2 are expressed in a wide variety of tissues. The estimated rate of neurological complications is 1–4.2% of patients, and neuromuscular disorders are the most common. Adverse effects on the central nervous system including encephalitis are less frequent. Here, a patient receiving anti-PD-1 antibodies showed cranial dura matter involvement, and the dura enhancement on MRI was resolved by withdrawal of the treatment with anti-PD-1 antibodies only.

Lanthanum chloride induces neuron damage by activating the nuclear factor-kappa B signaling pathway in activated microglia

Metallomics ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1277-1287 ◽  
Author(s):  
Licheng Yan ◽  
Jinghua Yang ◽  
Miao Yu ◽  
Yanxin Lu ◽  
Liling Huang ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Rare Earth ◽  
Adverse Effects ◽  
Signaling Pathway ◽  
Earth Element ◽  
Nuclear Factor Kappa B ◽  
Nuclear Factor ◽  
Neuron Damage ◽  
The Central Nervous System

Lanthanum is a rare earth element which can have adverse effects on the central nervous system (CNS).

scholarly journals Memantine as an Augmentation Therapy for Anxiety Disorders

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Thomas L. Schwartz ◽  
Umar A. Siddiqui ◽  
Shafi Raza
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Nmda Receptor ◽  
Adverse Events ◽  
Nmda Receptor Antagonist ◽  
Augmentation Therapy ◽  
Treatment Resistant ◽  
Excitatory Neurotransmitter ◽  
The Central Nervous System ◽  
Development Of Anxiety

Objective. Glutamate, an excitatory neurotransmitter in the central nervous system (CNS), may play a role in the development of anxiety. Memantine partially blocks N-methyl-D-aspartate (NMDA) receptors' glutamate channels located in the CNS. This paper evaluates memantine as an augmentation therapy for treatment of anxiety.Methods. 15 consecutive partially responding anxious patients were treated with adjunctive memantine for 10 weeks. Memantine was dosed 5–20 mg/day.Result. Memantine augmentation resulted in clinically relevant reduction in anxiety symptoms when compared to baseline. Forty percent of patients achieved remission (HAM-A ≥ 7). Memantine improved sleep quality. Mean dose was 14 mg/d (range 5–20 mg/d). Typical adverse events included nausea and headache.Conclusion. The NMDA receptor antagonist memantine may be an effective augmentation therapy in patients with treatment-resistant anxiety.

Central nervous system processing of emotions in children with nocturnal enuresis and attention-deficit/hyperactivity disorder

2014 ◽  
Vol 103 (8) ◽  
pp. 868-878 ◽  
Author(s):  
Monika Equit ◽  
Anna Becker ◽  
Diana El Khatib ◽  
Mathias Rubly ◽  
Nicolas Becker ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Attention Deficit Hyperactivity Disorder ◽  
Nervous System ◽  
Attention Deficit ◽  
Nocturnal Enuresis ◽  
Hyperactivity Disorder

Ifosfamide-induced encephalopathy in a patient with metastatic fibrosarcoma

Oncoreview ◽  
2016 ◽  
Vol 6 (4) ◽  
pp. 0-0 ◽  
Author(s):  
Łukasz Galus
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Adverse Effects ◽  
Toxic Effects ◽  
Cytostatic Drug ◽  
The Central Nervous System ◽  
The Common

Ifosfamide is a cytostatic drug commonly used in chemotherapy. One of the common adverse effects resulting from the treatment with ifosfamide is encephalopathy. This paper describes a case study of a 64-year-old patient who suffered from a full-blown encephalopathy as a result of chemotherapy administered during the treatment of fibrosarcoma of the femur. It provides a hypothesis of the mechanism behind toxic effects of ifosfamide on the central nervous system and elaborates on a number of documented ways of preventing aforementioned complications.

scholarly journals BIOLOGICAL MARKERS OF NON-CARCEROGENIC NEGATIVE IMPACTS ON THE CENTRAL NERVOUS SYSTEM OF CHILDREN IN THE AREA WITH EXPOSURE TO ALUMINUM PRODUCTION EMISSIONS

2018 ◽  
Vol 97 (5) ◽  
pp. 461-469
Author(s):  
I. G. Zhdanova-Zaplesvichko ◽  
Marina A. Zemlyanova ◽  
Yu. V. Koldibekova
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Aluminum Content ◽  
Negative Impact ◽  
Neuron Specific Enolase ◽  
Aluminum Production ◽  
Atmospheric Air ◽  
Hyperactivity Disorder ◽  
The Central Nervous System

Introduction. The priority indicator of the influence of chemical factors of the environment on the health of the population of Russia is the pollution of atmospheric air, the composition of which is largely determined by regional features of production. Material and methods. A comparative hygienic assessment of the quality of the atmospheric air of the territory with the placement of aluminum production and the territory without similar sources of emissions was conducted; a chemical-analytical and clinical laboratory examination of 135 children was carried out, with an assessment of the negative effects from the nervous system in the case of aerogenic exposure to aluminum and manganese. Results. In the conditions of the existing quality of atmospheric air in the residential area in the zone of influence of aluminum production which forms an aerogenic exposure of substances (aluminum and manganese), possessing of the unidirectional negative impact on the central nervous system, at the level of 0.0015g/(kg∙day) the share of aluminum is 93.3%, which indicates its primary impact on the population. Children of the observation group 1 showed urine aluminum content by 3.1 times more than in comparison to observation subgroup 2 and 6.9 times in relation to the comparison group (p = 0.0001). The concentration of aluminum as a marker of inhalation exposure is substantiated, and its value more than 0.053 mg/dm3 in urine may indicate an increased risk of neurotoxic exposure. An increased prevalence (1.6-5.5 times) of the negative impact on the CNS in the form of the asthenic autonomous syndrome, as a predictor of attention deficit and hyperactivity disorder, has been shown to be associated with the aerogenic exposure to aluminum. In children with an elevated aluminum content in urine comparing to the reference level, revealed laboratory abnormalities and indices were proved to be associated with an elevated concentration of aluminum in the urine relative to the children of the comparison group: an increase in the level of neuron-specific enolase in the serum indicating an increase in the activity of damage to the blood-brain barrier; an increase in the glutamic acid content by 1.3 times, characterizing the imbalance of the neurotransmitters of the central nervous system; reduction in serum phosphorus, reflecting the antagonistic effect of aluminum, followed by an increase in the level of ionized calcium in the blood. The contribution of aluminum to the biochemical and functional indices deviation from the physiological norm accounted for from 10% to 58%. On the basis of a consistent chain of reliable dependencies, a complex of biomarkers of the asthenic autonomous syndrome and attention deficit and hyperactivity disorder associated with an elevated aluminum content in urine, including glutamic acid, neuron-specific enolase, and phosphorus is substantiated.

Sign in / Sign up

Export Citation Format

Share Document